Neuroprotective Effect of Troxerutin against Cognitive Impairment in Type 2 Diabetes Mellitus Mice Model

Waqas Ahmad, Ikram Ullah, Ashfaq Ahmed Khan Malik, Farhan Younas, Muhammad Riaz

Abstract


Background: Type 2 diabetes (DM2T) is predominantly associated with obesity in people of all ages, both of which cause major worldwide morbidity and deaths. The present study evaluates the possible neuroprotective impact of troxerutin (TROX) in decreasing the cognitive impairment caused by DM2T.

Methods: Five groups of mice received different diets for nineteen weeks: a regular diet, TROX as a drug control group, diet rich in fat (HFD), streptozotocin (STZ) with HFD and HFD + STZ with TROX supplementation. The metabolic indicators such as daily food consumption, weekly body weight and body mass index were assessed. Other data points that were routinely observed were blood glucose level, insulin and glucose tolerance and behavioral evaluations. In brain homogenates and tissues the ROS level and antioxidant enzyme activities were assessed.

Results: The HFD group's body weight considerably increased in comparison to the control, drug control and HFD + STZ groups. Additionally, the HFD + STZ + TROX group had decreased the daily food consumption, enhanced body weight, adipose tissue weight, insulin/glucose tolerance and reduced glucose/fasting blood levels versus the HFD + STZ group. Furthermore, the TROX therapy improved anxiety symptoms and cognitive performance. Reduced antioxidant enzymes activities and a considerable enhancement in lipid peroxidation were observed in HFD+STZ group. The TROX treatment reduced these adverse effects by lowering lipid peroxidation and ROS level in mice brain.

Conclusions: According to these outcomes, TROX could be a helpful therapy for the management of DM2T and cognitive decline.

Keywords: Obesity, Troxerutin, neuroprotection, antioxidant enzyme, ROS.


Full Text:

PDF

References


Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol, (2018); 14(2): 88-98.

Reed J, Bain S, Kanamarlapudi V. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. Diabetes Metab Syndr Obes, (2021); 143567-3602.

IDF (2021) Diabetes: Facts and Figures.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, (2004); 27(5): 1047-1053.

IDF (2021) Diabetes in Pakistan.

Goyal R, Singhal M, Jialal I (2018) Diabetes mellitus type 2. Treasure Island (FL): StatPearls Publishing.

Biessels GJ, Reijmer YD. Brain Changes Underlying Cognitive Dysfunction in Diabetes: What Can We Learn From MRI? Diabetes, (2014); 63(7): 2244-2252.

Al Duhaidahawi D, Hasan SA, Al Zubaidy HFS. Flavonoids in the Treatment of Diabetes: Clinical Outcomes and Mechanism to Ameliorate Blood Glucose Levels. Curr Diabetes Rev, (2021); 17(6): e120720188794.

Anderson J. The Pharmacokinetic Properties of Glucagon-like Peptide-1 Receptor Agonists and Their Mode and Mechanism of Action in Patients with Type 2 Diabetes. The Journal of family practice, (2018); 67(6 suppl): S8-S13.

Anuradha CV. Phytochemicals targeting genes relevant for type 2 diabetes. Can J Physiol Pharmacol, (2013); 91(6): 397-411.

Zhang ZF, Fan SH, Zheng YL, Lu J, Wu DM, et al. Troxerutin protects the mouse liver against oxidative stress-mediated injury induced by D-galactose. J Agric Food Chem, (2009); 57(17): 7731-7736.

Panat NA, Maurya DK, Ghaskadbi SS, Sandur SK. Troxerutin, a plant flavonoid, protects cells against oxidative stress-induced cell death through radical scavenging mechanism. Food Chem, (2016); 19432-45.

Zhang ZF, Zhang YQ, Fan SH, Zhuang J, Zheng YL, et al. Troxerutin protects against 2,2',4,4'-tetrabromodiphenyl ether (BDE-47)-induced liver inflammation by attenuating oxidative stress-mediated NAD(+)-depletion. J Hazard Mater, (2015); 28398-109.

Zhang ZF, Fan SH, Zheng YL, Lu J, Wu DM, et al. Troxerutin improves hepatic lipid homeostasis by restoring NAD(+)-depletion-mediated dysfunction of lipin 1 signaling in high-fat diet-treated mice. Biochem Pharmacol, (2014); 91(1): 74-86.

Geetha R, Radika MK, Priyadarshini E, Bhavani K, Anuradha CV. Troxerutin reverses fibrotic changes in the myocardium of high-fat high-fructose diet-fed mice. Mol Cell Biochem, (2015); 407(1-2): 263-279.

Sampath S, Karundevi B. Effect of troxerutin on insulin signaling molecules in the gastrocnemius muscle of high fat and sucrose-induced type-2 diabetic adult male rat. Mol Cell Biochem, (2014); 395(1-2): 11-27.

Lu J, Wu DM, Hu B, Zheng YL, Zhang ZF, et al. NGF-Dependent activation of TrkA pathway: A mechanism for the neuroprotective effect of troxerutin in D-galactose-treated mice. Brain Pathol, (2010); 20(5): 952-965.

Khan Malik AA, Ahmad W, Younas F, Badshah H, Alharazy S, et al. Pretreatment with troxerutin protects/improves neurological deficits in a mouse model of traumatic brain injury. Heliyon, (2023); 9(7): e18033.

Kawamura N, Katsuura G, Yamada-Goto N, Novianti E, Inui A, et al. Impaired brain fractalkine-CX3CR1 signaling is implicated in cognitive dysfunction in diet-induced obese mice. BMJ Open Diabetes Res Care, (2021); 9(1): e001492.

Sarnyai Z, Sibille EL, Pavlides C, Fenster RJ, McEwen BS, et al. Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin(1A) receptors. Proc Natl Acad Sci U S A, (2000); 97(26): 14731-14736.

Nnoruka UC, Okonkwo CJ, Ilechukwu I, Okonkwo CJ, Belonwu DC. Impact of polystyrene microplastic exposure on lipid profile and oxidative stress status of male and female Wistar rats. Environ Anal Health Toxicol, (2022); 37(3): e2022024-2022020.

Ali T, Badshah H, Kim TH, Kim MO. Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE/NF-K B/JNK signaling pathway in aging mouse model. J Pineal Res, (2015); 58(1): 71-85.

Adekeye AO, Irawo GJ, Fafure AA. Ficus exasperata Vahl leaves extract attenuates motor deficit in vanadium-induced parkinsonism mice. Anat Cell Biol, (2020); 53(2): 183-193.

Lu J, Wu DM, Zheng YL, Hu B, Cheng W, et al. Troxerutin counteracts domoic acid-induced memory deficits in mice by inhibiting CCAAT/enhancer binding protein beta-mediated inflammatory response and oxidative stress. J Immunol, (2013); 190(7): 3466-3479.

Ali J, Khan AU, Shah FA, Ali H, Islam SU, et al. Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model. Life Sci, (2019); 239116888.

Zulfiqar Z, Shah FA, Shafique S, Alattar A, Ali T, et al. Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats. J Inflamm Res, (2020); 131185-1205.

Vargas-Soria M, Garcia-Alloza M, Corraliza-Gomez M. Effects of diabetes on microglial physiology: a systematic review of in vitro, preclinical and clinical studies. J Neuroinflammation, (2023); 20(1): 57.

Abbatecola AM, Arosio B, Cerasuolo M, Auriemma MC, Di Meo I, et al. Common neurodegenerative pathways in brain aging, cognitive decline, type 2 diabetes & metabolic syndrome. Journal of Gerontology and Geriatrics, (2024); 72(1): 43-49.

Chodari L. Troxerutin, a Bioflavonoid, Improves Oxidative Stress in Blood of Streptozotocin-Induced Type-1 Diabetic Rats: Troxerutin improves oxidative stress in diabetic rats. Iranian Journal of Pharmaceutical Sciences, (2017); 13(2): 75-86.

Yu Y, Zheng G. Troxerutin protects against diabetic cardiomyopathy through NF-κB/AKT/IRS1 in a rat model of type 2 diabetes. Molecular Medicine Reports, (2017); 15(6): 3473-3478.

Islam MS, Wilson RD. Experimentally induced rodent models of type 2 diabetes. Methods Mol Biol, (2012); 933161-174.

Liu S, Ma L, Ren X, Zhang W, Shi D, et al. A new mouse model of type 2 diabetes mellitus established through combination of high-fat diet, streptozotocin and glucocorticoid. Life Sci, (2021); 286120062.

Nath S, Ghosh SK, Choudhury Y. A murine model of type 2 diabetes mellitus developed using a combination of high fat diet and multiple low doses of streptozotocin treatment mimics the metabolic characteristics of type 2 diabetes mellitus in humans. J Pharmacol Toxicol Methods, (2017); 8420-30.

Kamli-Salino SEJ, Brown PAJ, Haschler TN, Liang L, Feliers D, et al. Induction of experimental diabetes and diabetic nephropathy using anomer-equilibrated streptozotocin in male C57Bl/6J mice. Biochem Biophys Res Commun, (2023); 650109-116.

Ahmadi Z, Mohammadinejad R, Roomiani S, Afshar EG, Ashrafizadeh M. Biological and therapeutic effects of troxerutin: molecular signaling pathways come into view. Journal of pharmacopuncture, (2021); 24(1): 1.

Zhang S, Li H, Zhang L, Li J, Wang R, et al. Effects of troxerutin on cognitive deficits and glutamate cysteine ligase subunits in the hippocampus of streptozotocin-induced type 1 diabetes mellitus rats. Brain Res, (2017); 1657355-360.

Chen R, Hassan H, Rawlinson C, Morgan D. Pharmacological properties of rutin and its potential uses for Alzheimer’s disease. Journal of Experimental Stroke Translational Medicine, (2020); 13(2): 1-12.

Malinska H, Huttl M, Oliyarnyk O, Markova I, Poruba M, et al. Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome. PLoS One, (2019); 14(8): e0220377.

Jafari-Khataylou Y, Emami SJ, Mirzakhani N. Troxerutin attenuates inflammatory response in lipopolysaccharide-induced sepsis in mice. Res Vet Sci, (2021); 135469-478.

Li H, Li J, Wang P, Yuan F, Zhang S. Improvement of actin dynamics and cognitive impairment in diabetes through troxerutin-mediated downregulation of TRPM7/CaN/cofilin. Neuropeptides, (2023); 102102381.

Zhà o H, Wang R, Zhang Y, Liu Y, Huang Y. Neuroprotective effects of troxerutin and cerebroprotein hydrolysate injection on the neurovascular unit in a rat model of Middle cerebral artery occlusion. International Journal of Neuroscience, (2020); 131(3): 264-278.




DOI: https://doi.org/10.62940/als.v13i2.3679

Refbacks

  • There are currently no refbacks.